Medlive Technology Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Liping Tian
Chief executive officer
CN¥4.8m
Total compensation
| CEO salary percentage | 35.8% |
| CEO tenure | 11.7yrs |
| CEO ownership | 1.1% |
| Management average tenure | no data |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Be Wary Of Medlive Technology (HKG:2192) And Its Returns On Capital
Dec 04
Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings
Oct 02Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now
Sep 27Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital
Jul 04Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price
Apr 08Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return
Feb 20Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?
Jan 10Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price
Sep 27Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return
Jul 10Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless
May 11Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)
May 02Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 26Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital
Feb 06There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital
Oct 31Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital
Jul 14These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts
Apr 03Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?
Feb 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥290m |
| Mar 31 2024 | n/a | n/a | CN¥266m |
| Dec 31 2023 | CN¥5m | CN¥2m | CN¥242m |
| Sep 30 2023 | n/a | n/a | CN¥216m |
| Jun 30 2023 | n/a | n/a | CN¥189m |
| Mar 31 2023 | n/a | n/a | CN¥153m |
| Dec 31 2022 | CN¥7m | CN¥2m | CN¥117m |
| Sep 30 2022 | n/a | n/a | CN¥83m |
| Jun 30 2022 | n/a | n/a | CN¥48m |
| Mar 31 2022 | n/a | n/a | CN¥44m |
| Dec 31 2021 | CN¥7m | CN¥1m | CN¥41m |
| Sep 30 2021 | n/a | n/a | CN¥55m |
| Jun 30 2021 | n/a | n/a | CN¥70m |
| Mar 31 2021 | n/a | n/a | CN¥78m |
| Dec 31 2020 | CN¥816k | CN¥816k | CN¥85m |
| Dec 31 2019 | CN¥756k | CN¥756k | CN¥31m |
| Dec 31 2018 | CN¥736k | CN¥736k | CN¥14m |
Compensation vs Market: Liping's total compensation ($USD663.01K) is above average for companies of similar size in the Hong Kong market ($USD478.76K).
Compensation vs Earnings: Liping's compensation has been consistent with company performance over the past year.
CEO
Liping Tian (57 yo)
11.7yrs
Tenure
CN¥4,839,000
Compensation
Ms. Liping Tian is Chairwoman and Chief Executive Officer of Medlive Technology Co. Ltd. Ms. Tian has been Executive Director of Medlive Technology Co. Ltd since April 2013. She has been the executive dire...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairwoman & CEO | 11.7yrs | CN¥4.84m | 1.1% HK$ 78.3m | |
| President | 11yrs | CN¥2.14m | 0.27% HK$ 19.4m | |
| VP, Deputy Head of Medical Information Science Research Unit & Executive Director | 11yrs | CN¥2.04m | 0.21% HK$ 15.2m | |
| VP & Executive Director | 6.4yrs | CN¥673.00k | no data | |
| Independent Non-Executive Director | 3.9yrs | CN¥120.00k | no data | |
| Non-Executive Director | 11yrs | no data | no data | |
| Independent Non-Executive Director | 3.9yrs | CN¥120.00k | no data | |
| Independent Non-Executive Director | 3.9yrs | CN¥120.00k | no data | |
| Non-Executive Director | 1.7yrs | no data | no data |
6.4yrs
Average Tenure
55yo
Average Age
Experienced Board: 2192's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 14:29 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medlive Technology Co., Ltd. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Shuo Song | Citic Securities Co., Ltd. |
| Justin Kwok | Goldman Sachs |